Unknown

Dataset Information

0

The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation.


ABSTRACT: Background:Tumor necrosis factor alpha (TNF?) is a key cytokine in both the pathogenesis of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) and the host defense against tuberculosis (TB). Consequently, anti-TNF? medications result in an increased risk of latent TB infection (LTBI) reactivation. Here, we sought to evaluate the factors affecting the results of QuantiFERON-TB Gold In-Tube (QFT-GIT) assay as a screening tool for LTBI. Methods:We conducted an observational, retrospective study in patients with IBD and RA who underwent LTBI screening using QFT-GIT at UMass Memorial Medical Center between 2008 and 2016 prior to initiation of anti-TNF medications. Results:We included 107 and 89 patients with IBD and RA, respectively. We found that a higher proportion of IBD patients had indeterminate QFT-GIT result compared to RA patients. Furthermore, we found that the majority of patients with indeterminate results were tested during an acute flare of IBD (88%) and while taking corticosteroids. Of all patients receiving ?20 mg equivalent prednisone dose (n=32), 63% resulted in indeterminate QFT-GIT, compared to only 6% indeterminate testing in patients receiving <20 mg of equivalent prednisone dose (n=164, P<0.001). There was no correlation between indeterminate results and age, gender, disease duration, or distribution, or smoking status within each population. Conclusion:We observed that high-dose corticosteroids may affect QFT-GIT outcomes leading to a high proportion of indeterminate results. We propose that IBD patients should be tested prior to initiation of corticosteroids to avoid equivocal results and prevent potential delays in initiation of anti-TNF medications.

SUBMITTER: Hakimian S 

PROVIDER: S-EPMC5834167 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation.

Hakimian Shahrad S   Popov Yevgeniy Y   Rupawala Abbas H AH   Salomon-Escoto Karen K   Hatch Steven S   Pellish Randall R  

Biologics : targets & therapy 20180227


<h4>Background</h4>Tumor necrosis factor alpha (TNFα) is a key cytokine in both the pathogenesis of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) and the host defense against tuberculosis (TB). Consequently, anti-TNFα medications result in an increased risk of latent TB infection (LTBI) reactivation. Here, we sought to evaluate the factors affecting the results of QuantiFERON-TB Gold In-Tube (QFT-GIT) assay as a screening tool for LTBI.<h4>Methods</h4>We conducted an observation  ...[more]

Similar Datasets

| S-EPMC7007987 | biostudies-literature
| S-EPMC3110578 | biostudies-literature
| S-EPMC7297367 | biostudies-literature
| S-EPMC5521843 | biostudies-other
| S-EPMC4281799 | biostudies-other
| S-EPMC6204680 | biostudies-literature
| S-EPMC7448650 | biostudies-literature
| S-EPMC10097492 | biostudies-literature
| S-EPMC3435391 | biostudies-literature
| S-EPMC10604336 | biostudies-literature